Trial Profile
A Phase 3 Randomized Controlled Study of Metronomic Capecitabine Combined With Aromatase Inhibitor Versus Aromatase Inhibitor Alone for First Line Treatment in Hormone Receptor-positive, Her2-negative Metastatic Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Anastrozole; Exemestane; Letrozole
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms MECCA
- 27 Jan 2023 Planned End Date changed from 1 May 2023 to 1 May 2024.
- 27 Jan 2023 Planned primary completion date changed from 1 May 2021 to 1 May 2024.
- 27 Jan 2023 Status changed from recruiting to active, no longer recruiting.